المؤلفون: Bensimon, Arielle G., Zhong, Yichen, Swami, Umang, Briggs, Allison, Young, Joshua, Feng, Yuan, Song, Yan, Signorovitch, James, Adejoro, Oluwakayode, Chakravarty, Abhiroop, Chen, Mei, Perini, Rodolfo F., Geynisman, Daniel M.

المصدر: Current Medical Research & Opinion; Sep2020, Vol. 36 Issue 9, p1507-1517, 11p

مصطلحات موضوعية: IPILIMUMAB, RENAL cell carcinoma, ADVERSE health care events, COST effectiveness, PROGRESSION-free survival, LIFE expectancy

المؤلفون: Albiges, Laurence¹ (AUTHOR) laurence.albiges@gustaveroussy.fr, Gurney, Howard² (AUTHOR), Atduev, Vagif³ (AUTHOR), Suarez, Cristina⁴ (AUTHOR), Climent, Miguel A⁵ (AUTHOR), Pook, David⁶ (AUTHOR), Tomczak, Piotr⁷ (AUTHOR), Barthelemy, Philippe⁸ (AUTHOR), Lee, Jae Lyun⁹ (AUTHOR), Stus, Viktor¹⁰ (AUTHOR), Ferguson, Thomas¹¹ (AUTHOR), Wiechno, Pawel¹² (AUTHOR), Gokmen, Erhan¹³ (AUTHOR), Lacombe, Louis¹⁴ (AUTHOR), Gedye, Craig¹⁵ (AUTHOR), Perini, Rodolfo F¹⁶ (AUTHOR), Sharma, Manish¹⁶ (AUTHOR), Peng, Xiang¹⁶ (AUTHOR), Lee, Chung-Han^1,17 (AUTHOR)

المصدر: Lancet Oncology. Aug2023, Vol. 24 Issue 8, p881-891. 11p.

مصطلحات موضوعية: *RENAL cell carcinoma, *KARNOFSKY Performance Status, *STROKE, *ADVERSE health care events, *PEMBROLIZUMAB, *HEART failure